Therefore, we asked if BQ could improve anticancer immunity in the B16F10 melanoma immunocompetent mouse model, which is typically refractory to dual ICB (i.e., anti-PD-1 plus anti-CTLA-4) (Twyman-Saint Victor et al., 2015). The gene discussed is CTLA4; the disease is melanoma.